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Abstract
Background: The incidence of anal cancer in human immunodeficiency virus (HIV)-positive individuals is increasing,
and how co-infection affects outcomes is not fully understood. This study sought to describe the current outcome
disparities between anal cancer patients with and without HIV undergoing abdominoperineal resection (APR).
Methods: A retrospective review of all US patients diagnosed with anal squamous cell carcinoma, undergoing an
APR, was performed. Cases were identified using a weighted derivative of the Healthcare Utilization Project’s
National Inpatient Sample (2000–2011). Patients greater than 60 years old were excluded after finding a skewed
population distribution between those with and without HIV infection. Multivariable logistic regression and
generalized linear modeling analysis examined factors associated with postoperative outcomes and cost.
Perioperative complications, in-hospital mortality, length of hospital stay, and hospital costs were compared for
those undergoing APR with and without HIV infection.
Results: A total of 1725 patients diagnosed with anal squamous cell cancer undergoing APR were identified, of
whom 308 (17.9 %) were HIV-positive. HIV-positive patients were younger than HIV-negative patients undergoing
APR for anal cancer (median age 47 years old versus 51 years old, p < 0.001) and were more likely to be male
(95.1 versus 30.6 %, p < 0.001). Postoperative hemorrhage was more frequent in the HIV-positive group (5.1 versus 1.
5 %, p = 0.05). Mortality was low in both groups (0 % in HIV-positive versus 1.49 % in HIV-negative, p = 0.355), and
length of stay (LOS) (10+ days; 75th percentile of patient data) was similar (36.9 % with HIV versus 29.8 % without
HIV, p = 0.262).
Greater hospitalization costs were associated with patients who experienced a complication. However, there was no
difference in hospitalization costs seen between HIV-positive and HIV-negative patients (p = 0.66).
Conclusions: HIV status is not associated with worse postoperative recovery after APR for anal cancer as measured
by length of stay or hospitalization cost. Further study may support APRs to be used more aggressively in HIV-
positive patients with anal cancer.
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Background
The incidence of squamous cell anal cancer in the last
decade has been increasing [1], and the disease dispro-
portionately affects HIV-positive individuals [2]. In non-
elderly populations, anal cancer affects approximately 46
in 100,000 HIV-positive men and 10 in 100,000 HIV-
positive women compared to 2 in 100,000 HIV-negative
men and negligible rates for HIV-negative women [3].
Increasing evidence suggests that the HIV-positive popu-
lation with anal cancer is distinctly different from the
historical squamous cell anal cancer population [4].
Amongst HIV-positive individuals, the risk of anal can-
cer diagnosis is 25 times higher [2, 5], and HIV infection
increases the risk of death from anal cancer by one to
four times [4, 6, 7]. HIV-positive patients with anal can-
cer are more likely to die of anal cancer than those with-
out HIV, and prior studies have suggested a less effective
initial treatment response in the HIV-positive population
to first-line anal cancer therapy [4, 8–12].
The National Comprehensive Cancer Network (NCCN)
Clinical Practice Guidelines in Oncology for anal carcin-
oma recommends chemoradiation therapy as the primary
treatment [13]. This recommendation arises from histor-
ical findings that the majority of patients who underwent
surgical resection had a complete pathological response
with no evidence of residual tumor in the pathological
specimen after neoadjuvant chemoradiation therapy was
administered. Chemoradiation rivals abdominoperineal
resection in that it preserves anal sphincter function
[14, 15]. For progressive and persistent disease, abdomino-
perineal resection is recommended.
Anal cancer is rare with less than 8000 reported cases
in the USA annually [1, 16], and recurrent anal cancer
eligible for salvage surgery is less than 5 % of total cases
[17, 18]. All studies of recurrent squamous cell anal can-
cer that go beyond observational survival statistics are
typically based on small case series usually reporting a
single institution’s experience of only 100 or fewer cases
[19, 20]. Moreover, the vast majority of these studies do
not examine the relationship between HIV infection and
anal cancer surgery outcomes even though the virus has
been implicated in the rise of anal cancer and its wors-
ening outcomes in recent years [1, 2, 4, 21]. Without lar-
ger case populations with good-quality data, the risk
factors, trajectories, and subgroup disparities have been
difficult to describe. This study aims to describe differ-
ences between anal cancer patients with and without
HIV undergoing abdominoperineal resection (APR).
Methods
Data collection
Under Institutional Review Board approval, selection cri-
teria for this study included all patients diagnosed with
squamous cell anal cancer undergoing APRs from
January 1, 2000 through December 31, 2011 using the
Agency for Healthcare Research and Quality’s (AHRQ)
Healthcare Utilization Project’s (HCUP) National In-
patient Sample (NIS). The NIS is the largest all-payer
inpatient healthcare database in the USA and, with
weighting, represents approximately 95 % (~20 % un-
weighted) of all hospitalized patients in the USA. Pa-
tients with anal cancer requiring an APR were identified
by the International Classification of Diseases, 9th
Revision (ICD-9) codes (anal cancer 154.2, 154.3; APR
48.5×), which were also used for comorbidity and com-
plication reporting (Additional file 1: Table S1). ICD-9
coding was also used to group patients with (042) and
without HIV as well as those with (86.7×) and without
perineal closure tissue flaps.
Study variables
Study variables were selected through a consensus-
driven selection process using the available variables in
the National Inpatient Sample and excluding those that
five experienced colorectal surgeons found to be unlikely
to be predictive of outcomes following abdominoperineal
resection. Patient demographics were included in the
study (e.g., age, sex, race) with age categorized into de-
cades. Hospital characteristics (e.g., teaching vs. non-
teaching hospital, urban vs. rural hospital) were included.
Categories of comorbidities (e.g., diabetes; cardiovascular,
liver, pulmonary, and renal) and postoperative com-
plications (e.g., renal, cardiac, respiratory, liver, and
gastrointestinal; deep venous thrombosis/pulmonary
embolism, wound and intra-abdominal infections, sep-
sis and septic shock, postoperative hemorrhage, re-
exploration) were identified using ICD-9 codes from
external sources [22]. In-hospital mortality was exam-
ined. Using hospital-specific cost-to-charge ratios pro-
vided by HCUP, hospitalization costs per patient were
derived. All dollar values were adjusted to 2011
equivalents.
Statistical analysis
HCUP NIS data was obtained with weighting to the size
of the US population. Continuous variables were com-
pared using the Mann-Whitney test of medians. Cat-
egorical variables were compared using the chi-square
test. Logistic regression models were used to examine
which factors determined extended length of stay. A
generalized linear model examined which factors in-
creased hospitalization costs. A modified Park test was
used to determine the appropriate distribution. Both
models were built using forward and backward selection
methods in which HIV status was forced into the
model and variables were retained in the model if
their p values were less than 0.20. A p value of <0.05
was considered statistically significant. All analyses
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were performed using Stata/MP® version 12.1 (StataCorp,
College Station, TX).
Results
Initially, a total of 3336 patients meeting selection cri-
teria were identified. Further analysis demonstrated that
the age distribution of HIV-negative patients with anal
cancer was bimodal, with a substantial portion greater
than age 60 while the HIV-positive population was nar-
rowly concentrated in a range less than 60 years old with
no HIV-positive patients with anal cancer greater than
60 years old. To control for age-related differences in
both populations, HIV-negative patients greater than
60 years old (n = 1611) were excluded from further ana-
lysis. The demographics of the excluded subset are in-
cluded in Table 1 for comparison.
After excluding elderly patients, a total of 1725 pa-
tients diagnosed with anal squamous cell cancer under-
going APR were identified. Three hundred eight patients
(17.9 %) were HIV-positive. HIV-positive patients were
younger than HIV-negative patients undergoing APR for
anal cancer with a median age of 47 versus 51 years (p <
0.001), and HIV-positive patients were also dispropor-
tionately male (95.1 versus 30.6 %, p < 0.001). There was
no statistical difference in race, comorbidities (diabetes,
cardiovascular, liver, pulmonary, renal), use of tissue
flaps for perineal closure, whether the surgery was per-
formed at a teaching hospital, and the type of commu-
nity (urban versus rural). The characteristics of the two
populations are presented in Table 1.
Postoperative APR outcomes were similar in both
groups (Table 2). The in-hospital mortality rate was 0 %
in HIV-positive versus 1.49 % in HIV-negative patients
(p = 0.36), and the proportion of patients having an “ex-
tended LOS” (10 days or more based on 75th percentile
of all patient stays) were similar (36.9 % with HIV versus
29.8 % without HIV, p = 0.26). The only significant dif-
ference in outcomes was that postoperative hemorrhage
was more frequent in the HIV-positive group (5.1 versus
1.5 %, p = 0.05). There was no difference in the propor-
tion of patients in each group developing any postopera-
tive complications (renal, cardiac, respiratory, liver,
gastrointestinal, venous thromboembolism, wound infec-
tions, and intra-abdominal infection, sepsis). The pres-
ence of one or more comorbidities increased the rate of
postoperative complications, which also contributed to a
longer hospital length of stay. However, there was no
difference between HIV-positive and HIV-negative pa-
tients having at least one comorbidity (p = 0.65).
Multivariable regression was used to determine which
factors significantly affected LOS and total hospitalization
costs. Forward and backward selection for each model re-
sulted in identical results. Regression analysis demon-
strated no difference in extended LOS according to HIV
status in the unadjusted (OR = 1.37, p = 0.26) and the ad-
justed (OR = 0.90, p = 0.79) model. However, male gender
(OR = 1.85, p = 0.02), the occurrence of a postoperative
complication (OR 5.00, p = 0.001), and the use of tissue
flaps (OR 2.60, p = 0.008) were associated with an in-
creased LOS (Table 3).
A generalized linear model was used to examine
hospitalization costs. A modified Park test demonstrated
that a gamma distribution was the best fit for
hospitalization costs. The adjusted model showed that
patients who experienced a complication, were treated
at a teaching hospital, were closed with perineal tissue
flaps, or had an extended length of stay also had greater
hospitalization costs of $6914, $5662, $5008, and
$21,162, respectively (all p < 0.001). However, there was
no difference in hospitalization costs seen between HIV-
positive and HIV-negative patients in both the un-
adjusted and the adjusted models (Table 4).
Discussion
This study highlights important differences between
those with and without HIV infection undergoing APR
for anal cancer. In a weighted, national sample of pa-
tients requiring APR for anal cancer, HIV-positive pa-
tients were more likely to be male and, on average,
younger than HIV-negative patients. However, this study
also found important similarities between these two sub-
populations with anal cancer requiring APR. Except for
postoperative hemorrhage, which was more common in
HIV-positive patients, there were no significant differ-
ences in complications, inpatient mortality, or length of
stay between HIV-positive and HIV-negative patients.
For median hospitalization costs, there was borderline
significance; however, further analysis adjusting for other
factors showed it to be both statistically insignificant.
Multivariable analysis demonstrated that the majority
of variance in length of stay is explained by the occur-
rence of complications, more complex perineal closures,
and the tendency for males to remain hospitalized longer
than females, rather than a direct association with HIV
infection. Gender differences were also found in
hospitalization costs with females having lower costs
than males. This trend may be driven by the larger num-
ber of males in the HIV-positive subset of anal cancer
patients and the association of male gender with in-
creased hospital length of stay following APR.
The limitations of our study deserve discussion. Many
limitations of this study are inherent to the HCUP NIS
database. First, this study was performed retrospectively
using a national sample of patients. It is possible that sur-
geon selection bias of whom was selected for APR versus
who was declined surgery may influence these results.
The database does not differentiate outcomes based on
surgeon experience or techniques for abdominoperineal
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Table 1 Patients' demographics and baseline characteristics
HIV− HIV+ P HIV− >60 years
Total N 1417 308 – 1611
N (%) N (%) N (%)
Patient characteristics
Age (years)a
Median (IQR) 51(46–56) 47(40–53) <0.001 72(66–79)
<40 98 (6.9 %) 80 (25.9 %) <0.001
41–50 567 (40.0 %) 119 (38.5 %)
51–60 752(53.0 %) 110 (35.6 %)
60–70 711 (44.2 %)
>70 900 (55.9 %)
Genderb
Male 432 (30.6 %) 293 (95.1 %) <0.001 649 (44.1 %)
Female 981 (69.4 %) 15 (4.9 %) 956 (55.9 %)
Racec
White 796 (77.9 %) 160 (60.6 %) 0.19 1020 (84.7 %)
Black 125 (12.3 %) 55 (20.7 %) 85 (7.0 %)
Hispanic 50 (4.9 %) 29 (10.8 %) 63 (5.2 %)
Asian 15 (1.5 %) ≤10(<4 %) 11 (0.8 %)
Native American ≤10 (<1 %) 0 0
Other 30 (2.9 %) 16 (6.0 %) 26 (2.1 %)
Comorbidities
Diabetes 144 (10.1 %) 25 (8.2 %) 0.64 223 (13.8 %)
Cardiovascular 9 (0.6 %) 0 0.51 134 (8.3 %)
Liver 19 (1.3 %) ≤10 (3 %) 0.85 16 (1 %)
Pulmonary 180 (12.7 %) 30 (9.7 %) 0.49 299 (18.6 %)
Renal 20 (1.4 %) ≤10 (3 %) 0.95 43 (2.6 %)
AIDS N/A ≤10 (3 %) N/A
No comorbidity 1089 (76.8 %) 252 (81.8 %) 1055 (62.4 %)
Any 1 comorbidity 286 (20.2 %) 47 (15.2 %) 508 (31.6 %)
Any 2 comorbidities 43 (3.0 %) 9 (2.9 %) 88 (5.5 %)
Any 3 comorbidities 0 0 ≤10 (0.6 %)
≥1 comorbidity 329 (23.2 %) 56 (18.1 %) 0.65 606 (37.6 %)
Perineal tissue flaps
With 191 (13.5 %) 49 (16.0 %) 0.58 113 (7.0 %)
Without 1226 (86.5 %) 259 (84.0 %) 1497 (93.0 %)
Hospital type
Teaching statusb
Teaching hospital 1067 (75.8 %) 239 (77.4 %) 929 (57.9 %)
Non-teaching hospital 340 (24.2 %) 70 (22.7 %) 0.80 676 (42.1 %)
Hospital locationb
Urban 1321 (93.8 %) 302 (98.1 %) 0.22 1469 (91.5 %)
Rural 87 (6.2 %) ≤10 (<3 %) 136 (8.48 %)
Small sample subsets that are non-zero but less than 11 patients are not reportable per HCUP NIS guidelines
aMedian age is based on unweighted data
bTotal numbers may not add up due to less than 1 % missing data
c25 % missing data on race (HIV− N = 1022; HIV+ N = 264; HIV− >60 N = 1204)
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resection. Long-term oncologic outcomes are also not
followed through the NIS. Although the NIS is a sample
of hospitalized patients from all US states and with appro-
priate stratified sampling represents 95 % of US inpatients,
it still relies on hospital-reported ICD-9 codes for all the
diagnoses and procedures studied here. The database con-
tains administrative-level data and has the potential for
coding errors and omissions. Hence, some components of
patients’ care may not be recorded in the NIS [23].
The low prevalence of anal cancer requiring APR fur-
ther limits this study’s conclusions. There are just over
7000 cases of anal cancer annually in the USA [1, 19],
and less than 5 % of these cases require APR (e.g., late-
stage disease, recurrent disease) [17, 18]. Furthermore,
patients over the age of 60 were excluded to prevent
confounding. The findings reported here are suggestive
of no difference between patients undergoing APR for
anal cancer with or without HIV infection, but the low
Table 2 Postoperative outcomes following APR for anal cancer, compared by HIV infection status
HIV− HIV+ P HIV− >60
Total N 1417 308 – 1611
N (%) N (%) N (%)
Postoperative complications
Renal 106 (7.5 %) 28 (9.1 %) 0.66 154 (9.6 %)
Cardiac ≤10 (<1 %) ≤10 (<3 %) 0.38 68 (4.2 %)
Respiratory 221 (15.6 %) 56 (17.8 %) 0.67 258 (16.0 %)
Liver 0 0 0 0
Gastrointestinal 15 (1.0 %) 0 0.43 29 (1.8 %)
Venous thromboembolism 16 (1.2 %) 0 0.42 30 (1.8 %)
Wound infection and intra-abdominal infection 200 (14.1 %) 39 (12.5 %) 0.74 209 (13.0 %)
Sepsis 40 (2.8 %) ≤10 (<3 %) 0.40 71 (4.4 %)
Postoperative hemorrhage 19 (1.4 %) 16 (5.1 %) 0.05 46 (2.8 %)
Re-exploration 0 0 0 0
Any complication 447 (31.5 %) 107 (34.7 %) 0.62 613 (38.1 %)
In-hospital mortality 21 (1.5 %) 0 (0 %) 0.36 46 (2.9 %)
Length of staya
Median (IQR) 8(6–12) 9(7–14) 0.13 9(7–14)
Extended LOS 423(29.8 %) 114 (36.9 %) 0.26 644(40.0 %)
Costb
Median (IQR) 20,124 (13,529–29,264) 23,908 (15,915–34,378) 0.08 19,618 (13,822–23,757)
Mean (95 % CI) 26,588 (23,169–30,008) 29,899 (23,115–36,683) 0.39 27,948 (25,035–30,861)
Small sample subsets that are non-zero but less than 11 patients are not reportable per HCUP NIS guidelines
aExtended LOS: more than10 days (based on the 75th percentile of the data)
bAdjusted for 2011$. Total N for costs HIV− = 1212; HIV+ = 252; HIV− >60 = 1363
Table 3 Multivariable logistic regression model for extended length of stay after APR for anal cancer
Variables Unadjusted OR (95 % CI) P value Adjusted OR (95 % CI) P value
HIV 1.37 (0.78–2.41) 0.26 0.90 (0.43–1.91) 0.79
Any complication 5.09 (3.21–8.07) <0.001 5 (3.11–7.98) <0.001
Tissue flap 4.09 (2.11–7.95) <0.001 2.60 (1.28–5.26) 0.008
Age (years)
<40 Reference Reference
41–50 0.59 (0.29–1.21) 0.15 0.68 (0.31–1.49) 0.34
51–60 0.81 (0.41–1.63) 0.57 0.89 (0.40–1.91) 0.76
Sex
Male Reference Reference
Female 0.55 (0.36–0.84) 0.01 0.54 (0.33–0.91) 0.02
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prevalence limits statistical power. One important
question for further exploration is whether the increased
incidence of postoperative bleeding seen in HIV-positive
patients—a relationship not previously seen—persists
across other HIV-positive surgical patients, a poten-
tial unrecognized “idiopathic HIV-related functional
coagulopathy”. However, it is important to note that
this is the largest population of anal cancer patients
undergoing APR ever studied, and there is no prac-
tical means to increase the size of the population
studied in the near term.
Finally, this study is unable to assess long-term results
regarding the post-hospital course of patients with anal
cancer following APR. The NIS does not have any data
following inpatient discharge, and the de-identified na-
ture of the data prevents linking of NIS patient records
to cancer databases that could potentially inform the
matter. An important question this study is not able to
answer is whether HIV infection status affects the long-
term course of anal cancer after APR, such as rate of re-
currence and overall survival.
Our hypothesis was that HIV-positive patients would
do worse following an APR than HIV-negative patients
due to recognized risk factors present in HIV-positive
patients like atypical disease presentation, poor wound
healing, and more expensive medical care [24–26]. How-
ever, our findings do not support this hypothesis. Our
analysis suggests that HIV infection has no independent
effect on perioperative mortality, length of stay, or
hospitalization costs after accounting for other factors.
This conclusion is contrary to conventional wisdom.
We believe there are two possible explanations for our
findings. First, it is possible that the HIV-positive pa-
tients in this study were substantially healthier than
historical populations previously studied. This study ex-
clusively used data after January 1, 2000, while much of
the previous literature examined HIV-associated disease
at the height of the AIDS epidemic in an era prior to the
introduction of highly active anti-retroviral therapy
(HAART). Many studies specifically highlight low CD4
cell counts as a causal link to morbidity [24, 25]. It is
also widely understood that CD4 cell counts rise with
initiation of HAART [27]. One explanation for the lack
of difference in outcomes between HIV-positive and
HIV-negative anal cancer patients undergoing APR is
that there may be little physiologic difference between
these two populations. In the current era, it is possible
that HIV-positive patients may no longer represent a
unique population when it comes to surgical care if their
HIV infection is well controlled on HAART. However, it
is likely that there is considerable HIV-related variability
within the population. For example, a 2012 study exam-
ined CD4 counts amongst HIV-positive patients under-
going chemotherapy for anal cancer and demonstrated
median CD4 cell counts <300 suggesting ongoing active
HIV infection [28]. Another limitation of the current
study is the lack of CD4 counts to stratify patients by de-
gree of immunosuppression.
An alternative explanation for the lack of significant
difference between the two subsets studied has more
concerning healthcare implications. Is it possible HIV-
positive patients are thought to be too high-risk for high
morbidity surgery like APRs and therefore being offered
less optimal therapies instead? Previous studies have
made the argument that APRs should be offered earlier
to high-risk patients with anal cancer [29, 30]. One
would expect HIV-positive patients to be disproportion-
ately represented amongst those needing an APR and
Table 4 Generalized linear modeling (gamma distribution) of total hospitalization costs after APR for anal cancer
Variables Adjusted exp:coefficienta (95 % CI) Mean difference in cost (2011$) P value
HIV 1.03 (0.86–1.22) 670 0.78
Any complication 1.29 (1.11–1.51) 6914 0.001
Tissue flap 1.20 (0.98–1.49) 5008 0.082
Age (years)
<40 Reference Reference
41–50 1.03 (0.83–1.29) 859 0.76
51–60 1.12 (0.89–1.50) 2923 0.33
Sex
Male Reference Reference
Female 0.89 (0.77–1.03) −3128 0.125
Teaching status
Non-teaching Reference Reference
Teaching 1.23 (1.08–1.41) 5662 <0.001
Extended LOS 2.20 (1.88–2.57) 21,162 <0.001
aExponential coefficients
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therefore should have worse outcomes. Perhaps the lack
of difference in outcomes seen here is indicative of the
need for liberalized selection of HIV-positive patients for
APR to optimize long-term outcomes. Future prospect-
ive studies may need to account for the inherent selec-
tion of optimal surgical candidates from the broader
population of those patients in which an APR for anal
cancer is indicated.
Conclusions
An 11-year retrospective study of the largest HIV popu-
lation of patients undergoing APR for anal cancer shows
that perioperative outcomes and costs are similar to
HIV-negative patients undergoing APR. Further study of
linked cancer datasets and prospective studies of HIV-
positive patients diagnosed with anal cancer are neces-
sary to better understand this phenomenon.
Additional file
Additional file 1: Table S1. ICD-9 codes grouped by categories for
patient comorbidities and in-hospital complications. (DOC 42 kb)
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